Ayerst's Inderene LA
Firm submitted ANDA suitability petition for combination of long-acting propranolol plus hydrochlorothiazide with triamterene. Ayerst plans to market capsules in 80/50/75 mg, 120/50/75 mg, and 160/50/75 mg strengths as a "convenient alternative for those patients previously stabilized on a therapeutic regimen of one Inderal LA capsule and one Maxzide tablet daily." The petition cites recent survey data indicating that concomitant use with hydrochlorothiazide/triamterene accounts for 7.7% of total propranolol use.
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.